<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://blog.athleticsmd.org/exercise-and-nutrition-for-frailty-in-gi-cancer-network-meta-analysis-finds-thin</loc><news:news><news:publication><news:name>AthleticsMD Clinical Desk</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-06T10:30:35.693Z</news:publication_date><news:title>Exercise and nutrition for frailty in GI cancer: network meta-analysis finds thin evidence</news:title></news:news></url><url><loc>https://blog.athleticsmd.org/ercesicm-2025-post-resuscitation-guidelines-scope-basis-and-what-the-abstract-om</loc><news:news><news:publication><news:name>AthleticsMD Clinical Desk</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-06T10:00:35.684Z</news:publication_date><news:title>ERC–ESICM 2025 post-resuscitation guidelines: scope, basis and what the abstract omits</news:title></news:news></url><url><loc>https://blog.athleticsmd.org/eloralintide-plus-tirzepatide-what-the-easd-2026-phase-2b-data-show</loc><news:news><news:publication><news:name>AthleticsMD Clinical Desk</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-05T10:30:35.247Z</news:publication_date><news:title>Eloralintide plus tirzepatide: what the EASD 2026 phase 2b data show</news:title></news:news></url><url><loc>https://blog.athleticsmd.org/tirzepatide-without-insurance-what-drives-the-cost</loc><news:news><news:publication><news:name>AthleticsMD Clinical Desk</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-05T10:00:35.240Z</news:publication_date><news:title>Tirzepatide without insurance: what drives the cost</news:title></news:news></url></urlset>